As the flagship research center for Ferring, scientists at FRI are focused on the development of first-in-class therapeutic peptides and proteins in our key therapeutic areas: reproductive health, urology and gastroenterology.
With capabilities in peptide drug design, pharmacology, biochemistry and preclinical ADME, FRI is committed to development of a portfolio of novel, innovative peptide pharmaceuticals to address areas of high unmet medical need.
FRI’s peptide chemistry technology and expertise enables in-depth modification of virtually all peptide/hormone families. Our scientists are able to custom design peptide therapeutics with improved pharmacodynamics, pharmacokinetics and pharmaceutical properties.
The resulting peptide drugs retain the core features and advantages of naturally-occurring peptides/hormones while overcoming their limitations.